GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2023: USD 47.30 M

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income is USD 47.30 M for the year ending December 31, 2023, a 44.72% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2022 was USD 32.68 M, a 15.90% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2021 was USD 28.20 M, a 63.96% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2020 was USD 17.20 M, a -22.52% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Operating Income for the year ending December 31, 2019 was USD 22.20 M, a 53.02% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years